fak/alk/ros1 inhibitor apg-2449
Generic: FAK/ALK/ROS1 Inhibitor APG-2449
fak/alk/ros1 inhibitor apg-2449: 1 clinical trial tracked.
fak/alk/ros1 inhibitor apg-2449 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about fak/alk/ros1 inhibitor apg-2449, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2449 in Patients With Advanced Solid Tumors
Primary endpoint: Maximum Tolerated Dose (MTD)
Interventionalopen165 targetStarted 2019-05Completion 2028-019 sites · ChinaAscentage Pharma Group Inc.